Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at AACR Annual Meeting

CALGARY, March 13 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that two abstracts covering preclinical work with reovirus are available today on the American Association for Cancer Research (AACR) website at, and on the Oncolytics website at Both presentations are scheduled to be delivered at the AACR Annual Meeting in San Diego, California April 12-16, 2008.

The first abstract, entitled "Targeting Multiple Myeloma with Oncolytic Viral Therapy" covers preclinical work using reovirus as a purging agent during autologous (harvested from the patient themselves) hematopoietic stem cell transplants for multiple myeloma. The results demonstrated that up to 70% of multiple myeloma cell lines tested showed reovirus sensitivity and reovirus induced cell death mediated through apoptosis. An oral presentation is scheduled to be delivered by Dr. Chandini Thirukkumaran of the Tom Baker Cancer Centre, Calgary, AB on Tuesday, April 15, 2008.

The second abstract, entitled "Radiation in Combination with Reolysin for Pediatric Sarcomas" covers preclinical work using reovirus in combination with radiation in mice implanted with pediatric rhabdomyosarcoma and Ewing's sarcoma tumours. The results demonstrated that the combination of reovirus and radiation significantly enhanced efficacy compared to either treatment alone in terms of tumour regression and event free survival. A poster presentation is scheduled to be delivered by Dr. Pooja Gidwani of the Albert Einstein College of Medicine, Bronx, New York on Tuesday, April 15, 2008.

"This exciting work highlights the potential of expanding the use of the reovirus to include being used as a purging agent during autologous blood stem cell transplants, as well as a treatment for childhood sarcomas," said Dr, Matt Coffey, Chief Scientific Officer of Oncolytics.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the abstract and materials presented on the AACR website and at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008
2. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
3. Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference
4. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
5. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
6. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
7. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
8. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
9. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
10. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
11. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
Post Your Comments:
(Date:10/12/2015)... ... 12, 2015 , ... Spirax Sarco, the leader in products and services for ... compact clean steam generator . This unit is a skid mounted system that ... and EN285 standards. The CMS-C 600 generator can produce up to a maximum ...
(Date:10/12/2015)... -- cell surface marker detection market is ... a new report by Grand View Research, Inc. This growth ... oncology diseases and other cell-associated disorders. --> cell ... 6.49 billion by 2022, according to a new report by ... attributed to rise in incidence of oncology diseases and other ...
(Date:10/12/2015)... CAESAREA, Israel , October 12, 2015 ... of the Dario™ Diabetes Management Solution, today announced its ... a patient case study at MobiHealth,s 5th EAI ... Focused on, "Transforming healthcare through innovations in mobile and ... London, England from October 14 - ...
(Date:10/12/2015)... ... 12, 2015 , ... NeuMedics Inc., is a specialty biopharmaceutical company focused on ... and chronically be administered as an eye drop, announced today it has been selected ... and taking place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio. ...
Breaking Biology Technology:
(Date:9/29/2015)... 2015  iDAvatars is excited to be named one of ... market. The official announcement was recently made at an invite-only ... San Francisco , where iDAvatars presented a ... Watson. "It is both an honor and a ... bring to market the cognitive power of IBM Watson in ...
(Date:9/28/2015)... SAN JOSE, Calif. , Sept. 28, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that Lenovo ... area touch fingerprint sensor, FS4202, for its latest smartphone, ... enables secure, password-free access to unlock the device and ... consumers. The feature-rich Natural ID FS4202 ...
(Date:9/10/2015)... Sept. 10, 2015 Report Details ... Reveals Selling Opportunities and Revenue Prospects to Help ... of biologics, especially new drug classes? Get the ... ahead with exclusive market data and industry knowledge, ... developments, results, opportunities and sales predictions. Visiongain,s ...
Breaking Biology News(10 mins):